Prescription -Drug price increases cost Americans billions


Here is a look at the seven drugs that the institute analyzed. The cost to the U.S. health care system was calculated after taking into account pharmaceutical company discounts and other discounts.

  • The price of Humira, which treats arthritis, increased by 9.6 percent. Price for USA: $ 1.4 billion.
  • The price of Promacta, which treats a blood disease called chronic immune thrombocytopenic purpura (ITP), increased by 14.1 percent. Price for USA: $ 100 million.
  • The price of Tysabri, a monoclonal antibody used to treat multiple sclerosis, increased by 4.2 percent. Price for USA: $ 44 million.
  • The price of Xifaxan, used to treat irritable bowel syndrome, increased by 3 percent. Price for USA: $ 44 million.
  • The price of Trokendi, used to prevent migraine headaches, increased by 12.4 percent. Price for USA: $ 36 million.
  • The price of Lupron Depot, used to treat endometriosis in women and prostate cancer in men, increased by 5.9 percent. Price for USA: $ 30 million.
  • The price of Krystexxa, used to treat chronic arthritis, increased by 5.2 percent. Price for USA: $ 19 million.

AARP continues the fight for lower drug prices

The results of the report are consistent with AARP Price Watch reports showing that price increases on branded goods continue to outpace inflation. The latest AARP report showed that in 2020, the prices of 260 commonly used drugs, whose prices AARP has followed since 2006, rose by 2.9 percent, while the general inflation rate was 1.3 percent.

AARP’s Fair Rx Prices Now campaign has focused on convincing federal and state lawmakers to take steps to lower prescription drug prices.

On November 19, the U.S. House of Representatives passed legislation that would provide some financial relief to patients. Under the Build Back Better Act, supported by AARP, Medicare would for the first time be able to negotiate the price of some drugs, the price of some insulin would be limited to $ 35 a month, drug manufacturers would face tax fines if they raise prices more than inflation, and the cost of Part D prescription drugs would be limited to $ 2,000 a year. The bill is now being moved to the U.S. Senate.

Dena Bunis covers Medicare, health care, health policy and Congress. She also writes the “Medicare Made Easy” column for AARP Bulletin. Bunis was an award-winning journalist and spent decades working for daily newspapers in metropolitan areas, including as an office manager in Washington for Orange County Register and as a health policy and workplace writer for News day.

.

Leave a Comment

Advertise